Stocks and Investing Stocks and Investing
Mon, July 29, 2024

Matt Miksic Maintained (ABT) at Buy with Increased Target to $143 on, Jul 29th, 2024


Published on 2024-10-28 12:52:54 - WOPRAI, Matt Miksic
  Print publication without navigation


Matt Miksic of Barclays, Maintained "Abbott Laboratories" (ABT) at Buy with Increased Target from $140 to $143 on, Jul 29th, 2024.

Matt has made no other calls on ABT in the last 4 months.



There are 5 other peers that have a rating on ABT. Out of the 5 peers that are also analyzing ABT, 0 agree with Matt's Rating of Hold.



These are the ratings of the 5 analyists that currently disagree with Matt


  • Vijay Kumar of "Evercore ISI Group" Maintained at Buy with Decreased Target to $120 on, Tuesday, July 2nd, 2024
  • Shagun Singh of "RBC Capital" Reiterated at Buy and Held Target at $125 on, Tuesday, June 4th, 2024
  • David Roman of "Goldman Sachs" Initiated at Strong Buy and Held Target at $121 on, Thursday, May 30th, 2024
  • Joanna Wiensch of "Citigroup" Maintained at Strong Buy with Decreased Target to $119 on, Wednesday, May 22nd, 2024
  • Joanne Wuensch of "Citigroup" Maintained at Strong Buy with Increased Target to $128 on, Wednesday, April 3rd, 2024
Contributing Sources